← Back

Wire · opportunities

FDA Approves First-in-Class Asundexian for Stroke Prevention

Published

10 November 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at medscape.com →

◆ Verified

Fusion42 · 10 November 2026 · Fusion42 review

The FDA has approved asundexian, a first-in-class factor XIa inhibitor, for use with antiplatelet therapy to reduce stroke risk in adults after mild-to-moderate noncardioembolic ischemic stroke or high-risk transient ischemic attack. Clinical trials showed a 26% reduction in recurrent ischemic stroke without a significant increase in major bleeding overall.

This Wire brief sits within Fusion42's coverage of Biotech, and 15 sources have reported it between 9 Nov 2026 and 19 Nov 2026.

◆ ◆ The Wire takeaway

You now have a new drug-approved tool to reduce stroke recurrence without raising major bleeding risk overall. This approval opens chances to develop stroke therapies with safer blood clot mechanisms than traditional options.

◆ Coverage

15 sources · first reported 9 Nov 2026 · latest 19 Nov 2026

◆ Related on Wire

◆ Topics

Biotechstroke-preventionFDA-approvalasundexianfactor-XIa-inhibitorclinical-trial